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Abstract
Background—This study examined whether varenicline (VAR), or naltrexone (NTX), alone or 
in combination, reduces alcohol drinking in alcohol-preferring (P) rats with a genetic 
predisposition toward high voluntary alcohol intake.
Methods—Alcohol experienced P rats that had been drinking alcohol (15% v/v) for 2 hrs/day for 
4 weeks were fed either vehicle (VEH), VAR alone (0.5, 1.0 or 2.0 mg/kg BW), NTX alone (10.0, 
15.0 or 20.0 mg/kg BW) or VAR + NTX in one of four dose combinations (0.5 VAR + 10.0 NTX, 
0.5 VAR + 15.0 NTX, 1.0 VAR + 10.0 NTX, or 1.0 VAR + 15.0 NTX) at 1 hour prior to alcohol 
access for 10 consecutive days and the effects on alcohol intake were assessed.
Results—When administered alone, VAR in doses of 0.5 or 1.0 mg/kg BW did not alter alcohol 
intake but a dose of 2.0 mg/kg BW decreased alcohol intake. This effect disappeared when drug 
treatment was terminated. NTX in doses of 10.0 and 15.0 mg/kg BW did not alter alcohol intake 
but a dose of 20.0 mg/kg BW decreased alcohol intake. Combining low doses of VAR and NTX 
into a single medication reduced alcohol intake as well as did high doses of each drug alone. 
Reduced alcohol intake occurred immediately after onset of treatment with the combined 
medication and continued throughout prolonged treatment.
Conclusions—Low doses of VAR and NTX, when combined in a single medication, reduce 
alcohol intake in a rodent model of alcoholism. This approach has the advantage of reducing 
potential side effects associated with each drug. Lowering the dose of NTX and VAR in a 
combined treatment approach that maintains efficacy while reducing the incidence of negative 
side-effects may increase patient compliance and improve clinical outcomes for alcoholics and 
heavy drinkers who want to reduce their alcohol intake.
Keywords
alcohol drinking; alcohol treatment; selectively bred rats; naltrexone; varenicline
Correspondence: Janice C. Froehlich, PhD, Indiana University School of Medicine, 975 West Walnut Street IB 424, Indianapolis, 
Indiana 46202-5124 Phone 317-274-1347 FAX 317-274-2695; jcfroeh@iu.edu. 
HHS Public Access
Author manuscript
Alcohol Clin Exp Res. Author manuscript; available in PMC 2017 September 01.
Published in final edited form as:
Alcohol Clin Exp Res. 2016 September ; 40(9): 1961–1970. doi:10.1111/acer.13157.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Introduction
Alcoholism is the most prevalent and widespread of all addictive diseases and development 
of effective treatments for alcohol abuse and alcoholism is a world-wide priority. Only three 
drugs have been approved by the FDA for the treatment of alcohol dependence: disulfiram 
(antibuse), acamprosate, and naltrexone (NTX; Trexan or Revia) (Anton et al., 2006). NTX 
is more effective than is acamprosate (Maisel et al., 2013) and exhibits better compliance 
than does disulfiram (Anton et al., 2006; Fuller et al., 1986), but it remains under-utilized 
because its efficacy is modest (Froehlich et al., 2003; O’Malley et al., 2003), it is not 
effective for all alcoholics (Kranzler et al., 2000; Krystal et al., 2001), and, when it is 
effective, many alcoholics fail to maintain initial treatment gains and relapse to heavy 
drinking (Anton et al., 2006; Krystal et al., 2001; Krishnan-Sarin et al., 2007). Clearly, 
additional medications for the treatment of alcohol abuse and alcoholism are needed.
Opioid antagonists were first shown to decrease alcohol drinking in rats selectively bred for 
high voluntary alcohol intake (Froehlich et al. 1990; 1991a; Froehlich and Li, 1991b). This 
preclinical work led to studies on the effects of naltrexone (NTX), a nonspecific opioid 
receptor antagonist, on alcohol drinking in humans. NTX decreases alcohol intake and 
reduces alcohol relapse rates in alcoholics and heavy drinkers (O’Malley et al., 1992; 
Volpicelli et al., 1992). It reduces the reinforcing effects of alcohol by antagonizing beta-
endorphin stimulated dopamine (DA) release in the brain during alcohol exposure (DiChiara 
and Imperato, 1988; Imperato and DiChiara, 1986; Koob et al., 1992). Subjects receiving 
NTX reported that the “high” they experienced from alcohol was less than they had 
previously experienced in the absence of NTX, and was less than they had expected to 
experience when they drank alcohol (Volpicelli et al., 1995). The alcoholics who “slipped” 
and drank alcohol while taking NTX consumed less alcohol than did those taking placebo, 
were able to stop drinking after a few drinks, and were less likely to drink to intoxication.
Varenicline (VAR), an α4β2 nicotinic acetylcholinergic receptor partial agonist, marketed as 
CHANTIX® in the United States, and as CHAMPIX® in Europe and elsewhere, was FDA 
approved for smoking cessation in 2006. Recent preclinical studies suggest that VAR also 
reduces alcohol, as well as nicotine, intake in rats and humans by blocking both alcohol and 
nicotine-induced excitation of the DA system (Chatterjee et al., 2011; Fucito et al., 2011; 
Mckee et al., 2009; Steensland et al., 2007). In a preliminary study, we found that VAR 
decreases alcohol intake in a rodent model of alcoholism; that is, in rats selectively bred for 
alcohol preference and high voluntary alcohol drinking (“P” rats). This agrees well with 
other reports that VAR reduces operant self-administration of alcohol in rats (Bito-Onon et 
al, 2011) and reduces alcohol drinking in Wistar rats induced to drink alcohol via the sucrose 
fade procedure (Steensland et al., 2007). In humans, a preliminary study in heavy alcohol 
drinking smokers reported that VAR (2.0 mg/day), compared to placebo, decreased alcohol 
craving, the number of drinks consumed, and the subjective reinforcing effects of alcohol 
(e.g., “high” or “intoxication”), and increased the likelihood of abstaining from drinking 
(McKee et al., 2009). The subjects were not deprived of nicotine in this study which 
indicates that VAR decreased alcohol drinking independent of its effects on nicotine. 
O’Malley and colleagues gave 30 heavy drinking smokers VAR (2.0 mg/day) or placebo for 
5 or 8 weeks and found that VAR was well tolerated, and compared to placebo, VAR 
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decreased alcohol craving as well as the number of heavy alcohol drinking days (Fucito et 
al., 2011).
Given that both VAR and NTX, when administered alone, can decrease alcohol drinking in 
rats and humans, we hypothesized that VAR and NTX, when combined, would act more 
effectively to decrease alcohol drinking than would either drug alone. The fact that VAR and 
NTX, when given alone, reduce alcohol drinking in both P rats and in heavy drinkers lends 
predictive validity to the use of P rats as a rodent model of alcoholism that is appropriate for 
characterizing the effects of combining VAR+NTX on alcohol drinking (Froehlich et al., 
2003; O’Malley et al., 2003). The current study addressed the following questions in P rats: 
(1) Does VAR+NTX in combination reduce alcohol intake more effectively than dose either 
drug alone? (2) Does a reduction in drinking occur quickly after onset of treatment with the 
combined drug? And (3) is the reduction sustained throughout prolonged administration?
MATERIALS AND METHODS
Subjects
Fifty-nine alcohol-naïve male P rats from the 77th generation of selective breeding for 
alcohol preference (P line) served as subjects in all studies except when blood alcohol 
concentration (BAC) was examined. In that study a subset of 15 of the 59 rats served as 
subjects. At the onset of the study, all rats were between 148 to 158 days of age. The rats 
were individually housed in stainless steel hanging cages located in an isolated vivarium 
with controlled temperature (21±1°C) and a 12 hour light/dark cycle with lights off at 0900 
hrs. Standard rodent chow (Laboratory Rodent Diet #7001, Harlan Teklad, Madison, WI) 
and water were available ad libitum. All experimental procedures were approved by the 
Indiana University Institutional Animal Care and use Committee and conducted in strict 
compliance with the NIH Guide for the Care and Use of Laboratory Animals.
Alcohol Solution
A 15% (v/v) alcohol solution was prepared by diluting 95% alcohol (ethanol) with distilled, 
deionized water. The alcohol solution and water were presented in separate calibrated glass 
drinking tubes and daily intakes were recorded to the nearest ml. Alcohol intake in mls was 
converted to g alcohol/kg BW prior to data analysis
Drug Preparation and Oral Delivery
Varenicline tartrate (VAR) (Pfizer Int., Groton, CT) and naltrexone hydrochloride (NTX) 
(Sigma-Aldrich, St. Louis, MO,) were dissolved in deionized, distilled water using 
sonication at 55°C. The stock solution containing drug was added to a sweetened gelatin 
solution comprised of berry flavored Jell-O and gelatin in distilled, deionized water. VAR 
and NTX, expressed as free base masses, were added to the gelatin solution to provide the 
following doses: 0.5, 1.0, and 2.0 mg of varenicline/3.0 ml solution/kg BW; 10, 15, and 20 
mg of Naltrexone /3.0 ml solution/kg BW; and 0.5 or 1 mg VAR + 15 mg NTX/3.0 ml 
solution/kg BW, and 0.5 or 1 mg VAR + 10 mg NTX/3.0 ml solution/kg BW. While still hot, 
the gelatin solution containing the drug(s) was aliquoted into star shaped molds, one per rat, 
with the volume of each aliquot determined by the final concentration of the gelatin (mg 
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drug/ml of gelatin solution) and the body weight of the animal in order to produce individual 
drug dosing, one dose per day per rat, as previously described (Froehlich et al., 2013a). The 
flavored, star-shaped pieces of gelatin (approximately 1.8 g), containing VAR and NTX, 
alone or in combination, were fed to the rats once each day by inserting them through a hole 
in the front of the cage. The rats consistently ate the gelatin within 1 minute. Cages were 
checked to confirm that no pieces of gelatin were dropped. On the rare occasion that rats 
dropped the gelatin star, the star was re-fed to the rat. Gelatin was fed each day at 1 hour 
prior to onset of the daily 2-hour alcohol access period, except in one study where the time 
between oral drug delivery and onset of VAR treatment was the dependent variable. All rats 
were fed vehicle gelatin (no drug) once a day for 5 consecutive days prior to the initiation of 
drug treatment in order to acquaint them with the oral drug administration procedure. We 
have previously found that consumption of the flavored gelatin with no drug (vehicle) at 1 
hour prior to daily 2-hour access to alcohol does not alter alcohol intake (data not shown). 
Specifically, the average daily 2-hour alcohol intake during the 5 days prior to consumption 
of vehicle gelatin was 1.8 g/kg BW (N = 64 adult male P rats) and average daily 2-hour 
alcohol intake in the same rats during 5 days of consumption of vehicle gelatin was 1.7 g/kg 
BW. We routinely use this oral drug delivery approach successfully for the prolonged 
administration of drugs such as prazosin, NTX, or varenicline (Froehlich et al., 2013a, 
2013b). It is appropriate for any drug that is water soluble and orally active.
Alcohol Drinking Induction
All rats were provided with access to food, water and a 15% (v/v) alcohol solution and the 
alcohol solution was introduced using a “step-down” procedure as previously described 
(Froehlich et al, 2013a; 2013b) in order to maximize alcohol intake during a restricted two 
hour daily alcohol access period. Alcohol was first available for 8 hours a day for 5 days, 
then access was reduced to 4 hours a day for 10 days, and finally to 2 hours a day for 28 
days. Throughout each study rats were maintained with free access to food and water and 
scheduled access to the 15% (v/v) alcohol solution for 2 hours a day (from 1000 hours, onset 
of dark, to 1200 hours). Alcohol and water intake were recorded daily and body weight was 
recorded once a week. This step-down procedure produces stable drinking at approximately 
2.0g/kg BW/2 hours in P rats (Rasmussen et al., 2009). All rats had served as subjects in a 
prior study with varenicline, 11 weeks earlier, and were maintained with ad lib food and 
water and 2-hr daily access to alcohol (15% v/v) for 4 additional weeks prior to introducing 
the alcohol drinking induction protocol.
Assigning Rats to Groups
Rats were ranked in descending order of average daily 2h alcohol intake for 5 consecutive 
days prior to onset of drug treatment and were assigned to dose groups in a manner that 
ensured that alcohol intake did not differ between groups prior to initiation of drug 
treatment, as previously described (Froehlich et. al., 2013a; 2013b).
Experimental Design
Varenicline on alcohol intake—Rats were fed VAR (0.5, 1.0, 2.0 mg/kg BW) or vehicle 
in gelatin 1-hr prior to onset of each daily 2-hr alcohol access period for 5 days/week for 2 
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weeks. This was followed by continued ad libitum access to food, water, and continued daily 
2h access to alcohol without drug for 2 weeks (post drug days). In order to assess whether a 
longer lead time between drug administration and alcohol access would increase the efficacy 
of VAR, a subset of forty-nine male P rats were randomly selected and were fed vehicle 
gelatin stars at 2 hours prior to onset of daily 2-hour alcohol access for 5 days and daily 
alcohol intake was assessed. They were then assigned to VAR drug dose groups as 
previously described and were fed VAR (0.5, 1.0, or 2.0 mg/kg BW) or vehicle, once daily, 
at 2 hours prior to onset of the daily 2 hour alcohol access period for 5 consecutive days. 
Doses of VAR above 2.0 mg/kg were not used because higher doses of VAR are no longer 
specific for the alpha-2-beta-4 and/or alpha-7 nicotine acetylcholine receptors (Rollema et. 
al., 2006; conversation with Hans Rollema), and doses above 3.0 mg/kg decrease food intake 
in rats, presumably via induction of nausea (O’Conner et. al, 2009; Faessel et al., 2006).
Naltrexone on alcohol intake—Rats were fed NTX (10.0, 15.0, or 20.0mg/kg BW) or 
vehicle in gelatin stars at 1 hour prior to onset of each daily 2 hour alcohol access period for 
5 days a week for 2 weeks.
Varenicline + Naltrexone Combined—Another group of alcohol naïve adult male P rats 
(N=59) were induced to drink alcohol as described above. They were then maintained with 
ad lib food and water and 2-hr daily access to alcohol (15% v/v) for 4 weeks prior to onset 
of drug treatment. All rats were counterbalanced and assigned to drug dose groups as 
described above. Rats were fed vehicle or VAR + NTX (0.5 VAR+ 10.0 NTX or 0.5 VAR 
+ 15.0 NTX or 1.0 VAR + 10.0 NTX or 1.0 VAR + 15.0 NTX) in gelatin stars at 1 hour prior 
to onset of each daily 2-hr alcohol access period for 5 days a week for 3 weeks. The VAR 
and NTX doses that were chosen to be combined were those that were ineffective in 
decreasing alcohol intake when given alone.
Varenicline + Naltrexone on blood alcohol concentration (BAC)—After 
completion of the VAR+NTX study, 15 P rats were randomly selected from that study and 
were maintained with ad libitum access to food and water and limited access to alcohol 
(15% v/v) for 2 hours a day for 5 weeks. The rats were counterbalanced based on alcohol 
intake and assigned to the vehicle or the drug treatment group as described above. The rats 
were fed gelatin stars gummies containing no drug (vehicle) or containing 1.0 mg VAR + 10 
mg NTX/kg BW at 1 hour prior to onset of the daily 2-hour alcohol access period for 5 days 
prior to an intragastric (IG) infusion of alcohol and determination of BAC. It is known that 
naltrexone alone does not alter BAC (Linesman et al., 1997) but the effect of VAR on BAC 
is not known. We chose the highest dose of VAR that had been used in combination with 
NTX so that if the drug combination did alter BAC, it would be seen at this dose. On the 
night before IG infusion and BAC determination food was removed from all rat’s cages and 
each rat was given 7 grams of food which served to minimize and equate the amount of food 
present in the stomach at time of IG infusion of alcohol. This serves to reduce individual 
differences in the rate of alcohol absorption from the stomach, and reduces variability in 
BAC following an alcohol infusion. On the day of BAC determination, rats were given IG 
alcohol in a dose of 2.0 g alcohol/10.1 mls of a 25% v/v alcohol solution/kg BW. This dose 
is similar to the amount of alcohol that P rats consume in a daily 2-hr alcohol access period 
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(Froehlich et al., 2013a; 2013b; Froehlich et al., 2015; Rassmusen et al., 2009). This dose 
produces physiologically relevant BACs (Murphy et al. 1986) that are almost twice the 
human legal limit for intoxication (Li et al., 1998), but are below the threshold that produces 
damage to the gastric mucosa (Gillespe and Lucas, 1961) or that induces smooth muscle 
paralysis (Bernard et al., 1964). The volume infused is also well below the gastric capacity 
of an adult rat (Bull and Pitts, 1971). Tail blood was collected at 15, 30, 60, 90, 120, 180, 
and 240 minutes after onset of the IG alcohol infusion. A razor blade was used to cut the tip 
(< 1 mm) of the tail and 0.075 ml of blood was collected into a heparinized capillary tube, 
dispensed into an ice-cold 0.5-ml microcentrifuge tube, sealed, and centrifuged at 4 °C. 
Spontaneous bleeding stopped immediately after sample collection and subsequent samples 
were collected by removing the coagulate from the tip of the tail. Plasma was extracted and 
frozen at −20°C until assayed for alcohol content by gas chromatography using a Hewlett-
Packard 6890 series gas chromatography with auto injection. The column used was a HP-
Innowax (crosslinked polyethylene glycol, 30 m x 0.25 mm x 0.25 um), and the internal 
standard was 1-propanol.
Data Analysis
Alcohol intake was analyzed using 2-way repeated-measures analysis of variance (ANOVA) 
(treatment X day, RM on day) followed, when justified, by pairwise multiple comparisons 
using either Fisher’s least significant difference (LSD) test when the interaction term was 
significant or Dunnett’s multiple comparisons against a single mean when the interaction 
term was not significant. Significance was accepted at p<0.05, and data are represented as 
means ± SE. BACs were analyzed using a 2-way repeated-measures ANOVA (dose x time, 
with RM on time). Data were analyzed for extreme scores using the Dixon extreme score 
test and a conservative cutoff of p<0.01. Only 3 scores (in experiment 2) were excluded from 
the data set prior to statistical analyses. Extreme scores were replaced with the mean alcohol 
intake on the day prior to, and the day following the day when the extreme score was 
recorded. Consumption of less than ¾ of the gelatin star resulted in exclusion of the drinking 
score for that rat on that day which occurred 4 times in the NTX alone study and 1 time in 
the VAR 1 hour lead time study.
RESULTS
Alcohol Drinking Induction
During the first phase of alcohol drinking induction, P rats consumed roughly 4.0 g 
alcohol/kg BW per day during an 8-hr free-choice between the alcohol solution (15% v/v) 
and water. This corresponds to a 70-kg person (154 pounds) drinking 5–6 standard drinks. A 
standard drink contains approximately 14 g of alcohol (NIAAA, 2008). The alcohol 
elimination rate (AER) of rats is 0.44 g/kg BW/hour (Parselak et al., 2004), which is 
approximately 4 times the AER of humans (0.11 g/kg BW/h) (Forsander and Sinclair, 1992). 
During drinking induction, when the daily alcohol access period was reduced to 2 hours a 
day, the P rats consumed an average of approximately 2.0 g alcohol /kg BW, which is 
equivalent to a human drinking 3 drinks in two hours (Figure 1).
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Effect of VAR alone on Alcohol Intake (1 hour lead time)
Alcohol intake during the 2 weeks of VAR treatment (5 days/week) was analyzed with a 
two-way RM ANOVA (dose X day, RM on day). There was a significant effect of dose, F (3, 
55)= 9.284, p<0.001, a significant effect of day, F (9, 495) = 10.23, p<0.001, and no 
significant interaction (p=0.78) (Figure 2 A). Dunnett’s multiple comparisons against a 
single mean revealed that only the 2.0 mg/kg BW dose of VAR significantly reduced alcohol 
intake (p<0.001) when compared to vehicle (Figure 2 B). To further assess the effect of day, 
one-way ANOVAs were conducted, one for each of the 10 days of treatment, for VAR in a 
dose of 2.0 mg/kg BW. VAR reduced alcohol intake on all 10 days of drug treatment 
(p<0.05; p<0.01; or p<0.001, depending on the day) when compared to vehicle.
With regard to alcohol intake following termination of drug treatment, there was a strong 
trend toward a significant effect of dose (p=0.06), a significant effect of day [F(4, 220)= 
11.22, p<0.001], and no interaction (p=0.55) (Figure 2 A). Visual inspection of the data 
revealed that the trend for dose was due to the 2.0 mg/kg BW dose of VAR which was 
further analyzed with separate one-way analyses, one for each post drug day, comparing 2.0 
VAR and VEH. There was a very strong trend toward a reduction of alcohol intake on day 1 
following termination of drug treatment (p=0.053), but no significant effect was seen on any 
days thereafter.
Effect of VAR Alone on Alcohol Intake (2 hour lead time)
The two-way RM ANOVA (dose x day, RM on day) on days 1–5 of drug treatment revealed 
a significant effect of dose, F (3, 44)= 2.91, p<0.05, no significant effect of day (p=0.12), 
and no significant interaction (p=0.77). Dunnett’s multiple comparisons against a single 
mean revealed that no dose significantly decreased or increased alcohol consumption when 
compared to vehicle (Figure 3).
With regard to alcohol intake following termination of treatment, there was no effect of dose 
(p=0.95), a significant effect of day [F(4, 175)= 3.17, p<0.05], and no interaction (p=0.52).
Effect of NTX alone on Alcohol Intake
Alcohol intake during the 2 weeks of NTX treatment (5 days/week) was analyzed using a 
two-way RM ANOVA (dose X day, RM on day). The results revealed that there was a 
significant effect of treatment, F (3, 55)= 7.04, p<0.001, a significant effect of day, F (9, 
495)= 5.87, p<0.001, but no significant interaction (p=0.32) (Figure 4 A). Dunnett’s 
multiple comparisons against a single mean revealed that only the 20 mg dose of NTX 
significantly reduced (p<0.001) alcohol intake when compared with vehicle (Figure 4 B).
One-way ANOVAs were conducted, one for each day, to analyze how long the treatment 
effect of 20.0 mg NTX/kg BW lasted. The ANOVAs revealed that 20.0 NTX reduced 
alcohol intake on all 10 days of drug treatment when compared to vehicle (p<0.05, p<0.01, 
or p<0.001 depending on the day) (Figure 4 A).
With regard to alcohol intake following termination of treatment, there was no effect of dose 
(p=0.17), a significant effect of day [F(4, 220)= 7.80, p<0.001], and no interaction (p=0.82).
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Effect of VAR+NTX on Alcohol Intake
Alcohol intake during the first week of combination drug treatment (days 1–5) was analyzed 
with a two-way RM ANOVA (treatment X day with repeated measures on day). There were 
significant effects of treatment, F (4, 54) = 15.27, p<0.001, and day, F (4, 216) = 3.98, p 
<0.01, but no significant interaction (p=0.32). Dunnett’s multiple comparison against a 
single mean revealed that alcohol intake in all 4 combination drug treatment groups was 
significantly lower than intake in the vehicle treated group (p<0.001) (Figure 5B).
Alcohol intake during the entire 3 weeks of combination drug treatment (5 days/week) was 
analyzed with a two-way RM ANOVA (dose X day, with repeated measures on day). There 
were significant effects of treatment, F (4, 54) = 8.07, p<0.001, and day F (14, 756) =15.84, 
p<0.001, and a significant treatment x day interaction, F (56, 756) = 1.83, p<0.001 (Figure 5 
A). Fisher’s LSD test revealed that alcohol intake in all dose combination groups was 
significantly lower than alcohol intake in the vehicle treated group [0.5 VAR + 10 NTX 
(p=0.055), 0.5 VAR + 15 NTX (p<0.05), 1.0 VAR + 10 NTX (p<0.001), 1.0 VAR + 15 NTX 
(p<0.001)] (Figure 5 C). Fisher’s LSD test also revealed that alcohol intake in the highest 
VAR dose groups (1.0 VAR + 10 NTX and 1.0 VAR + 15.0 NTX), was significantly lower 
than intake in the 0.5 VAR dose groups (p<0.01 and p<0.01 respectively) regardless of the 
NTX dose that VAR was combined with. Further pairwise comparisons with Fisher’s LSD 
revealed that, when compared to VEH, 1.0 VAR + 15.0 NTX reduced alcohol intake on 14 
of the 15 treatment days (p<0.05, p<0.01, or p<0.001, depending on the day), 1.0 VAR 
+ 10.0 NTX reduced alcohol on 11 of the 15 treatment days (p<0.05, p<0.01, or p<0.001, 
depending on the day), 0.5 VAR + 15.0 NTX reduced alcohol intake on 6 of the 15 treatment 
days (p<0.05, p<0.01, or p<0.001, depending on the day), and 0.5 VAR + 10.0 NTX reduced 
alcohol intake on only 5 of the 15 treatment days (p<0.05, p<0.01, or p<0.001, depending on 
the day).
With regard to alcohol intake after termination of VAR+NTX treatment (Figure 5 A), there 
was no effect of treatment (p=0.68), or day (p=0.17), and no interaction (p=0.94).
Effect of VAR+NTX on BAC
With regard to the effect of 5 days of treatment (VAR 1.0 mg/kg BW +NTX 10.0 mg/kg 
BW) on BAC, a 2-way rm ANOVA (treatment X time with repeated measure on time) 
revealed no significant effect of treatment (p=0.74), a significant effect of time (p<0.001), 
and no significant interaction (p=0.69). The peak BAC was 150–170 mg% at 30–90 minutes 
after I.G. infusion with 2.0 g alcohol /kg BW in both the group pretreated with vehicle and 
in the group pretreated with 1.0 mg/kg VAR + 10 mg/kg NTX (Figure 6 A).
With regard to the alcohol intake during the 5 days of treatment (VAR 1.0 mg/kg BW +NTX 
10.0 mg/kg BW) prior to BAC determination, there was a significant effect of dose [F(1, 
16)= 7.38, p<0.05], no effect of day (p=0.08), and no interaction (p=0.92). Dunnet’s post-
hoc analysis revealed that the treatment of 1.0 VAR + 15 NTX reduced alcohol intake when 
compared to vehicle (Figure 6 B).
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DISCUSSION
Given the global prevalence of alcohol addiction, it is critical that people seeking help have 
access to effective treatments including medications as well as psychosocial interventions. 
Currently there are only three FDA approved drugs for the treatment of alcohol addiction: 
disulfiram (antibuse) which was approved in 1949, naltrexone (Trexan) which was approved 
in 1994, and acamprosate (campral) which was approved in 2004. None of these drugs are 
effective for all alcoholics and none are without side effects. Clearly, additional medications 
are needed to assist alcoholics and heavy drinkers in reducing their alcohol intake when they 
seek treatment on a voluntary basis as well as when treatment for alcohol abuse is delivered 
in closed care facilities.
Our research group has had a long-standing interest in identifying medications that have the 
potential to reduce alcohol abuse and alcoholism safely and effectively. Naltrexone has been 
extensively characterized in both rodents and humans (for review see Froehlich et al., 2003; 
O’Malley et al., 2003) and is the most effective medication available for decreasing alcohol 
intake (Maisel et al., 2013). However, NTX is underutilized because its efficacy is modest, it 
is not without side effects, it is not effective for all alcoholics, and, when it is effective, a 
number of alcoholics fail to maintain initial treatment gains and relapse to heavy drinking. 
We have recently begun to investigate the potential value of combining naltrexone with other 
medications in order to allow efficacy to be achieved at lower doses thus avoiding potential 
side effects. For instance, we have found that prazosin, a drug used to treat post-traumatic 
stress disorder (PTSD), decreases alcohol drinking in a rodent model of alcoholism when 
administered alone (Froehlich et al., 2013a; Froehlich et al., 2015; Rasmussen 2009) and 
combining low dose NTX with low dose prazosin, in a single medication, decreases alcohol 
drinking more effectively than does either drug alone (Froehlich et al., 2013b).
The current study focused on varenicline (Chantix or VAR), a relatively new drug that has 
been well characterized with regard to its effect on nicotine intake. VAR is marketed for, and 
used to, decrease cigarette smoking but a few studies have reported that it also decreases 
alcohol intake (Bilo-Onon, 2011; Chatterjee et al., 2011; Ericson et al., 2009). For instance, 
a recent study of cigarette smokers, who also drank alcohol heavily, reported that while VAR 
decreased smoking, as expected, a combination of VAR and NTX also reduced alcohol 
drinking and, when compared to placebo, reduced the “high” produced by alcohol (Ray et al, 
2014). This may be due, in part, to the fact that NTX and VAR share a common mechanism 
of action with regard to the dopaminergic system. Alcohol stimulates the release of 
endogenous opioids (for review see Froehlich and Li 1993; 1994) which in turn results in an 
increase in DA release in the nucleus accumbens (Di Chiara and Imperato 1988; Imperato 
and Di Chiara 1986; Weiss et al., 1993). This increase in DA release mediates the euphoria 
that accompanies alcohol drinking and that serves to reinforce subsequent alcohol drinking 
(Samson et al., 1992). NTX blocks opioid receptors which results in decreased alcohol-
induced DA release in the nucleus accumbens (Benjamin et al., 1993; Dudek et al., 2016) 
thus reducing alcohol-induced euphoria and the reinforcing properties of alcohol. VAR also 
decreases DA release in the nucleus accumbens by binding to the α4β2 nicotinic receptors 
(Rollema et al., 2007; Hendrickson et al., 2013). Hence, both naltrexone and varenicline 
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reduce alcohol-induced euphoria and alcohol reinforcement through inhibition of alcohol-
induced DA release.
Based on our prior work with drug combinations (Froehlich et al., 2013b; Rasmussen et al., 
2014; 2015), we predicted that combining an ineffective dose of NTX with an ineffective 
dose of VAR in a single medication would decrease alcohol intake more effectively than 
would either drug alone. The results of the current study support this prediction. During 
week one of treatment low doses of VAR (0.5, and 1.0 mg/kg BW) and low doses of NTX 
(10mg, and 15mg/kg BW), when given alone, were not effective in decreasing alcohol 
drinking. However, when ineffective doses of the two drugs were combined, alcohol intake 
was significantly reduced when compared to vehicle, and the effect was seen in all low dose 
combinations tested. Of particular importance is the fact that the reduction in alcohol 
drinking occurred immediately after onset of treatment with the combined medication and 
continued throughout 3 weeks of treatment. The low dose combination decreased alcohol 
intake as effectively as did higher doses of VAR (2.0 mg/kg BW) or NTX (20mg/kg BW) 
alone. The reduction in alcohol intake seen following VAR+NTX treatment was not due to 
drug-induced changes in alcohol absorption or clearance as evidenced by a similar 
magnitude and time course of the BAC following an IG infusion of alcohol in rats previously 
treated for 5 days with the drug combination (1.0 VAR + 10.0 NTX) or with vehicle. The 
drug combination decreased alcohol intake on all five days of treatment but did not alter 
BAC in response to an IG infusion of alcohol.
The ability of VAR alone, NTX alone and VAR+NTX to decrease alcohol intake 
disappeared after termination of drug treatment. However, there was a strong trend toward a 
significant effect of high dose VAR in reducing alcohol intake on the day following 
termination of treatment which suggests that the duration of action of VAR may surpass that 
of NTX.
The doses of NTX used in the current study (10.0 – 20.0 mg/kg BW) are higher than those 
used via non-oral routes. This is because NTX has a low bioavailability when administered 
orally (Hussain et al., 1987). Consequently, a larger dose is required to produce a 
comparable serum level of NTX to that seen when lower doses are given via non-oral routes. 
In rats, NTX has an oral bioavailability of 1%, which is lower than the 15–25% 
bioavailability found in humans (Goodman and Gilman, 2011). This low oral potency of 
NTX in rats is due to a rapid first pass metabolism, rather than to gastro-intestinal factors 
(Shepard et al., 1985). In contrast, varenicline is well absorbed after oral administration and 
has a bioavailability of >87% (Obach et al. 2005; and Goodman and Gilman, 2011). 
Therefore, a given dose of varenicline is equally effective if given via non-oral or oral routes 
(Steensland et al., 2007; Mckee et al., 2009). We are not aware of any interactions between 
NTX and VAR that would alter side effects associated with the combination in rodents or 
humans.
When administered orally in rodents (via gavage), the t1/2 of varenicline is 4.0 +/− 0.9 hours 
(Obach et al., 2005). In the current study, we compared the effect of two lead times, 1 hour 
and 2 hours, between oral administration of VAR and onset of access to alcohol. We found 
that VAR (2.0 mg/kg BW) was effective in reducing alcohol intake when given one hour 
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prior to onset of alcohol access, but was not effective when given two hours prior to alcohol. 
The 1 hour lead time appears optimal for VAR-induced reductions in alcohol drinking when 
administered orally in rodents.
It should be noted that neither VAR nor NTX, alone or in combination, eliminated alcohol 
drinking in P rats. While elimination of drinking (complete abstinence), can be achieved by 
humans, this usually occurs when psychosocial approaches are combined with medication in 
individuals with a high motivation to stop drinking. Rats lack the psychosocial elements 
(counseling, network support, social pressure) that contribute significantly to abstinence in 
humans and hence an elimination of alcohol drinking would not be expected in the current 
study in which rats received medication alone. The fact that varenicline + naltrexone, in a 
combined medication, reduced alcohol drinking without the contribution of psychosocial 
elements suggests that these drugs may be particularly effective for alcoholics and heavy 
drinkers who are motivated to reduce their drinking through the use of medications together 
with psychosocial interventions as part of a comprehensive treatment program for alcohol 
use disorders.
Using lower doses of drugs in combination has two potential benefits. First, use of low doses 
may eliminate adverse side effects. This is important with regard to NTX, which can 
produce occasional malaise, depression-like symptoms, and dysphoria (Hollister et al., 1981; 
Malcolm et al., 1987; Oncken et al., 2001) and with regard to VAR which can produce sleep 
disorders, increased fatigue, and jaundice in the case of drug-induced liver injury (Mogensen 
et al., 2015; Thomas et al., 2015). In the current study, a low dose of VAR+NTX was as 
effective in decreasing alcohol intake as was a high dose of either drug alone even during the 
first week of drug treatment. The fact that low dose VAR+NTX was effective in the first 
week of treatment, when the probability of relapse in alcoholics is high, is important because 
inpatients are typically instructed to abstain from alcohol for several days before starting a 
drug treatment, during which time alcohol craving escalates (personal conversation, Dr. Tim 
Kelley, Medical Director, Fairbanks Alcohol and Drug Treatment Center, 2012). A fast 
acting medication may help prevent relapse in these patients. For those in the outpatient 
setting, increased effectiveness of a combined medication in the first week of treatment is 
likely to promote a positive long-term outcome because an immediate positive effect may 
reinforce the decision to continue voluntary treatment (Christensen, 1978).
There is an urgent need for new approaches to treat alcoholism and alcohol abuse. A single 
medication may not be optimal for all stages of alcohol abuse or for different types of 
alcohol use disorders. A “personalized medicine” or “precision medicine” approach would 
allow for tailoring of drug combinations to meet the needs of individual patients. The results 
of the current study suggest that a combination of low dose VAR + NTX, may be effective 
when used early in the treatment process by alcoholics and heavy drinkers who do not 
respond well to a single medication.
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Figure 1. 
Alcohol intake in male P rats given scheduled access to alcohol (15% v/v) for 8 hours a day 
for 4 days, followed by 4 hours a day for 10 days, and 2 hours a day for 28 days prior to the 
initiation of drug treatment. Each point represents the mean ± SE.
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Figure 2. 
(A) Effect of oral varenicline (VAR) (0.5, 1.0 or 2.0 mg/kg BW) or vehicle (VEH), given 
one hour prior to alcohol access, on alcohol intake in male P rats given access to alcohol 
(15% v/v) for 2 hours a day. (B) Effect of VAR or VEH on mean alcohol intake over the 10 
days of drug treatment. *** p<0.001 vs VEH. Each point represents the mean ± S.E.
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Figure 3. 
Effect of oral varenicline (VAR) (0, 0.5, 1.0, or 2.0 mg/kg BW) or vehicle (VEH), given two 
hours prior to alcohol access, on alcohol intake in male P rats given access to alcohol (15% 
v/v) for 2 hours a day. Each point represents the mean ± S.E.
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Figure 4. 
(A) Effect of oral naltrexone (NTX) (10.0, 15.0, or 20.0 mg/kg BW) or vehicle (VEH) on 
alcohol intake in male P rats given access to alcohol (15% v/v) for 2 hours a day. (B) Effect 
of NTX or VEH on mean alcohol intake over the 10 days of drug treatment. *** p<0.001 vs 
VEH. Each point represents the mean ± S.E.
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Figure 5. 
(A) Effect of oral varenicline + naltrexone (VAR + NTX) (0.5 + 10.0, 0.5 + 15.0, 1.0 + 10.0, 
or 1.0 + 15.0 mg/kg BW) or vehicle (VEH) on alcohol intake in male P rats given access to 
alcohol (15% v/v) for 2 hours a day. (B) Effect of VAR+NTX VEH on mean alcohol intake 
over the first 5 days of drug treatment. (C) Effect of VAR+NTX or VEH on mean alcohol 
intake over the full 15 days of drug treatment. * p<0.05, ** p<0.01, ***p<0.001 vs VEH. 
Each point represents the mean ± S.E.
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Figure 6. 
(A) Effect of oral varenicline + naltrexone (VAR+NTX) (1.0mg + 10.0mg) or vehicle (VEH) 
on blood alcohol concentration (BAC) following an intragastric (IG) infusion of alcohol (2.0 
g/kg BW) in P rats. (B) Effect of VAR+NTX (1.0 + 10.0 mg/kg BW) or VEH on alcohol 
intake in the P rats depicted in (A) during the 5 days of drug treatment preceding BAC 
determination. Each point represents the mean ± S.E.
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